By Barbara Obstoj-Cardwell. Editor
Teva Pharmaceuticals’ announcement on Monday that it will voluntarily suspend sales, marketing and distribution of its Zecuity migraine relief product will likely have little impact on the company, analysts have said.
"Zecuity is a very small product for Teva with minimal sales contribution to the overall company," said Evercore ISI analyst Umer Raffat, the idea being that Zecuity was to have a presence in the headache community "ahead of the far more important anti-CGRP (calcitonin gene-related peptide) launch in a couple of years."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze